Hillsdale Investment Management Inc. Invests $226,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Hillsdale Investment Management Inc. acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 17,003 shares of the company’s stock, valued at approximately $226,000. Hillsdale Investment Management Inc. owned 0.07% of Eton Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eton Pharmaceuticals in the 3rd quarter valued at about $54,000. Jane Street Group LLC acquired a new position in shares of Eton Pharmaceuticals in the third quarter valued at approximately $90,000. Raymond James Financial Inc. purchased a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $147,000. Baader Bank Aktiengesellschaft acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $373,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after buying an additional 30,167 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Trading Up 4.0 %

Eton Pharmaceuticals stock opened at $14.79 on Tuesday. The stock has a market cap of $396.64 million, a P/E ratio of -67.23 and a beta of 1.37. The company has a fifty day simple moving average of $15.59 and a 200-day simple moving average of $11.71. Eton Pharmaceuticals, Inc. has a 12-month low of $3.03 and a 12-month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The business had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $10.53 million. As a group, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ETON has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Craig Hallum increased their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, March 19th. Finally, B. Riley reissued a “buy” rating and set a $24.00 price objective (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.